President Trump this afternoon announced two drug pricing rules with implications for the 340B program, and said his administration “in a few weeks” will finalize finalize regulations to require federally qualified health centers (FQHCs) to pass along 340B drug discounts on insulin and injectable epinephrine directly to patients. | Source: White House YouTube channel.
Trump Issues Drug Pricing Rules That Impact 340B; Says 340B Health Center Final Rule Is Coming
Medicare-participating 340B hospital outpatient departments will have to take part in the Trump administration’s “most favored nation” (MFN) payment test for Medicare Part B drugs, the U.S. Health and Human Services Department announced late today.
“To the extent these entities receive payment under the model that is lower than their current Medicare payment, there may be fewer resources available for their 340B program activities,” the Centers for Medicare & Medicaid Services (CMS) acknowledged in an interim final rule posted for public inspection this afternoon. The rule takes effect Jan. 1, 2021. CMS is accepting public comments; the deadline is 5 p.m. on Jan. 26, 2021.
.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.